BioPharma Resources

Drug Trial Radar · NCT04742959

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

203

Actual

Start

Mar 14, 2021

Primary completion

Feb 20, 2024

Study completion Feb 20, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor
  • Cholangiocarcinoma
  • HER2-negative Breast Cancer
  • Triple Negative Breast Cancer
  • Bladder Cancer
  • Small-cell Lung Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Sarcoma
  • Gastric Cancer
  • Gallbladder Cancer

Interventions

  • TT-00420Drug

    TT-00420 tablet will be administered orally once daily per protocol defined schedule.

  • Nab-PaclitaxelCombination product

    Nab-Paclitaxel would be administered via infusion on Day 1,8, and 15 of 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to TreatmentTime frame: Up to 30 days from study discontinuation
  2. Dose limiting toxicity (DLT)Time frame: Up to 28 days from the first dose

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • The University of Chicago

    Chicago, Illinois

  • Rutgers Cancer Institute

    New Brunswick, New Jersey

  • Gabrail Cancer Center Research

    Canton, Ohio

  • UT Southwestern Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.